DCN-1 Modulating Compounds for Fetal Hemoglobin Induction
Solution Overview
Problem
There is a need for therapeutic agents and therapies to treat hemoglobin-related disorders such as sickle cell disorders and thalassemia, as existing treatments are inadequate in addressing the underlying causes of these conditions.
Innovation Solution
Compounds and compositions that modulate DCN-1, inducing fetal hemoglobin production to treat hemoglobin-related disorders, including sickle cell disorders and thalassemia, are developed.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for hemoglobin-related disorders, then current standard of care is maintained, but underlying causes of the conditions are not addressed
Solution Approach 1:
The patent changes the therapeutic parameter from symptomatic management to targeted molecular intervention by modulating DCN-1 protein expression levels. This parameter change enables the treatment to address the underlying molecular cause of hemoglobinopathies rather than merely managing symptoms, thereby improving both reliability and adaptability of the treatment approach
2Productivity
If DCN-1 modulation is implemented to induce fetal hemoglobin production, then fetal hemoglobin production is induced, but the mechanism involves complex protein-protein interactions
Solution Approach 1:
The patent extracts and targets the specific DCN-1 protein component within the complex neddylation pathway. By focusing on this single protein as the therapeutic target, the invention simplifies the approach to inducing fetal hemoglobin production despite the underlying complexity of protein-protein interactions in the cullin-RING ligase system
Solution Approach 2:
The patent introduces small molecule compounds as intermediaries that modulate DCN-1 function. These small molecules serve as mediators between the therapeutic goal and the complex molecular machinery, enabling control of fetal hemoglobin production without requiring direct manipulation of the complex protein-protein interaction network
Data Source
AI summary
The present disclosure provides DCN-1 modulating compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions, and their use for treating sickle cell disorders, diseases, and conditions. Such compounds are of Formula Ia:or a pharmaceutically acceptable salt thereof.